Uproleselan Plus Chemotherapy Could Provide MRD Benefit in Relapsed/Refractory AML Rory M. Shallis, MD Yale Cancer Center #leusm #oncology onclive.com/view/uprolesel…

Featured today by MSK Library: Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated... dx.doi.org/10.1016/j.leuk… Rory M. Shallis, MD Dr. Anthony Stein Guido Marcucci Amer Zeidan MBBS,MHS ‏عامر زيدان shai shimony Maximilian Stahl

Day 13: use of FLT3 and IDH inhibitors in AML previously treated Ven-based therapy by @Dr_roryshallis Amer Zeidan MBBS,MHS ‏عامر زيدان @maxstahlmd & others #leusm
- ORR 17% and median OS4.2 months
- lack of response in patients with RAS pathway mutations

sciencedirect.com/science/articl…

A pleasure to discuss the importance of the TP53 evaluation in higher-risk MDS with VuMedi. Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp vumedi.com/video/the-impo…

Tune in tonight at 7:30pm to Yale Cancer Center Answers to hear Rory M. Shallis, MD discuss the role of #AgentOrange in the development of certain cancers, and his role in caring for patients with #MDS . Listen live on Connecticut Public or download our podcast from iTunes. Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp

Join us next Thursday, July 14th at 11 am EST for a new HealthTree Podcast for AML episode!
Rory M. Shallis, MD from Yale School of Medicine will join us to discuss the TP53 mutation in AML and current treatment options, clinical trials, and drugs targeting this mutation.
bit.ly/3c03Esf

Join us this Saturday, May 21st @ 12:00 pm ET for our virtual 'Precision Medicine in MDS and AML' webinar with speaker Rory Shallis, MD.

Register today: bit.ly/37GVVOl

A recent paper published in Leukemia & Lymphoma Taylor & Francis Research Insights by Yale Cancer Center Rory M. Shallis, MD and Dr. Steven Gore nick, gives a clearer overview of #AgentOrange in the development of #AML and #MDS bit.ly/3MFjwxH. Smilow Cancer Hospital Yale New Haven Hosp Yale School of Medicine YaleHematology

University of Chicago Hematology/Oncology Day 3: a very comprehensive review by Rory M. Shallis, MD Maximilian Stahl Amer Zeidan MBBS,MHS ‏عامر زيدان on newly-diagnosed TP53-mutated AML #leusm

mdpi.com/2673-6357/2/4/…

Another blow dealt in the myeloid malignancy ring. N=154 patients with mTP53 MDS, AZA+APR-246 vs. AZA monotherapy. Primary endpoint CR 33.3% vs. 22.4%; p=0.13). Await secondary endpoint data. globenewswire.com/news-release/2…

NEW CLINICAL TRIAL NOW ENROLLING - VERONA STUDY

Do you or someone you know have newly diagnosed Higher-Risk Myelodysplastic Syndrome (MDS)? If so, this trial may be of benefit for you!

Despite their imparted “functional cure,” TKIs are not received by one-third of older patients with newly-diagnosed CML. I provide more details during our oral presentation tomorrow 9:00-9:15AM PST Yale COPPER Center Yale Cancer Center Amer Zeidan MBBS,MHS ‏عامر زيدان Scott Huntington ash.confex.com/ash/2020/webpr…

A take on CRh as an endpoint for AML with Daniel Pollyea and Amer Zeidan MBBS,MHS ‏عامر زيدان. Palpable benefits but much still undetermined. thelancet.com/journals/lanha…

Check out our thorough and provocative discussion on “myeloid sarcoma” and it’s management sciencedirect.com/science/articl…!

4 days until #HemOnc & #COVID19 Sessions Webinar!

Join Amer Zeidan MBBS,MHS ‏عامر زيدان, Jan Bewersdorf, John Mascarenhas & Rory M. Shallis, MD for a discussion on managing hematological malignancies during COVID19

Register here 👉ow.ly/j9oQ50AGkVz👈

#Leukemia #Leusm #ALL #CML #MPN #MDS #AML

#HemOnc & #COVID19 Sessions: managing hematological malignancies during COVID-19

Exclusive broadcast w/ Amer Zeidan MBBS,MHS ‏عامر زيدان, Jan Bewersdorf, John Mascarenhas & Rory M. Shallis, MD

28th July @ 5PM CEST

Register here 👉ow.ly/fmMj50AEPx9

#Leukemia #Leusm #ALL #CML #MPN #MDS #AML

ICYMI—Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts #COVID19 #leusm thelancet.com/journals/lanha…

Today has been the most important day in terms of high quality publications on COVID-19. Up to now amazingly 15425 manuscripts have been published in scientific journals. However 4 of the top 10 papers ever published on COVID-19 were published today. #COVIDー19 #Coronavirus 1/5

Dr. Lohith Gowda presenting at #TCTM20 Infection and Immune Reconstitution Working Committee proposing a study to evaluate the impact of time-to-transplant on the outcomes of AML/ALL/MDS patients Yale Cancer Center Yale Medicine Yale New Haven Health